Work Here?
About StimLabs
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Seed
Total Funding
$10M
Headquarters
Roswell, Georgia
Founded
2015
Overview
StimLabs develops and sells advanced healing solutions derived from placental tissue, focusing on regenerative medicine. Their products help the body repair and regenerate damaged tissues, catering to healthcare providers, hospitals, and clinics seeking to improve patient outcomes. StimLabs uses proprietary processing techniques that set them apart from competitors, allowing for significant advancements in the placental tissue market. The company prioritizes regulatory compliance and quality control, ensuring their products are safe and effective for patient use. Their goal is to be a trusted partner in enhancing patient care through innovative regenerative solutions.
Simplify's Take
What believers are saying
- Partnership with Geistlich Pharma expands StimLabs' wound care product portfolio.
- Growing demand for regenerative treatments aligns with StimLabs' innovative healing solutions.
- Advancements in cryopreservation enhance the efficacy of StimLabs' placental tissue products.
What critics are saying
- Increased competition in regenerative medicine could threaten StimLabs' market share.
- Potential patent disputes may lead to costly legal battles for StimLabs.
- Changes in healthcare reimbursement policies could impact StimLabs' revenue streams.
What makes StimLabs unique
- StimLabs uses proprietary techniques for placental tissue processing, offering a competitive edge.
- The company focuses on regenerative healing, promoting tissue repair and regeneration.
- StimLabs emphasizes regulatory compliance and quality control, building trust with healthcare providers.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$10M
Above
Industry Average
Funded Over
0 Rounds
Benefits
Professional Development Budget
Flexible Work Hours
Company News
Geistlich Pharma has entered an exclusive national distribution collaboration agreement with StimLabs in the US, focusing on the commercialisation of the former's Advanced Wound Matrix, Derma-Gide.
WOLHUSEN, Switzerland-(BUSINESS WIRE)-Geistlich Pharma AG, a worldwide leader in regenerative technologies, announced an exclusive national distribution partnership agreement with StimLabs of Roswell, GA.
New Partnership Expands StimLabs Product Offering to Include Medicare Covered Xenograft, Derma-Gide (Q4203)ROSWELL, Ga., Nov. 26, 2024 /PRNewswire/ -- StimLabs, a leading regenerative medicine company, announced that it has entered into an exclusive national distribution agreement with Geistlich to commercialize an innovative wound care product line, beginning with the advanced wound matrix, Derma-Gide®. This strategic partnership broadens the StimLabs product portfolio to include xenografts and continues the company's history of bringing unique regenerative solutions to the market
StimLabs has launched Corplex P in the United States.
StimLabs introduces Corplex P wound care device in US.
StimLabs is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today
About StimLabs
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Seed
Total Funding
$10M
Headquarters
Roswell, Georgia
Founded
2015
StimLabs is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today